Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of “Buy” by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $13.71.

Several equities research analysts have issued reports on HUMA shares. TD Cowen reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th.

Humacyte Trading Down 0.7 %

NASDAQ:HUMA opened at $4.27 on Friday. The stock has a market capitalization of $537.42 million, a PE ratio of -3.19 and a beta of 1.30. Humacyte has a 1-year low of $2.81 and a 1-year high of $9.97. The firm has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $5.46.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same quarter in the prior year, the company earned ($0.25) EPS. On average, equities analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura E. Niklason sold 811,172 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock valued at $6,606,799 in the last quarter. Company insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

A number of institutional investors have recently modified their holdings of HUMA. State Street Corp grew its position in Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Humacyte by 1,018.4% during the 2nd quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after purchasing an additional 233,422 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of Humacyte by 60.7% during the 4th quarter. Private Advisor Group LLC now owns 599,700 shares of the company’s stock valued at $3,028,000 after purchasing an additional 226,590 shares during the last quarter. Finally, LJI Wealth Management LLC bought a new position in Humacyte in the 4th quarter valued at approximately $934,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.